If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Single-Dose Mometasone Furoate Improves Asthma Control, Regimen Adherence in Adolescents and Young Adults: Presented at ACAAI By Micheal Casasnovas MIAMI BEACH, Fla -- November 13, 2009 -- Adolescents and young adults can achieve higher adherence levels with asthma medication, have fewer asthma-like attacks, and use fewer short-acting beta2-agonist canisters as rescue medication if they are prescribed mometasone furoate dry powder inhaler. The study, based on research into insurance claims, was presented here at the American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting, on November 8. “Improved adherence and asthma control in the mometasone furoate inhaler treatment group may have been due to the once-daily dosing regimen indicated for mometasone furoate inhaler compared with those of a non-mometasone furoate inhaled corticosteroid, which are primarily indicated for twice-daily dosing,” said Prakash Navaratnam, PhD, Eympres Research LLC, Columbus, Ohio. Dr. Navaratnam and colleagues retrospectively analysed the insurance claims database to determine asthma control and adherence among adolescents and young adult patients with mild asthma receiving mometasone furoate inhaler or a non-mometasone furoate inhaled corticosteroids. Researchers included patients aged 12 to 25 years diagnosed with mild asthma and who received prior non-inhaled corticosteroids asthma therapy. They reviewed data on individuals who received their first prescription for mometasone furoate inhaler or another inhaled corticosteroid from January 1, 2005, to October 1, 2007. The patients also had to be enrolled in their health plan for at least 1 year before and after their index date. “Adolescents and young adults are among the most difficult-to-treat patients with asthma,” said Dr. Navaratnam. “Limiting daily medication dosage may help to increase adherence among adolescent and young adult patients with asthma. Among patients with asthma, increased adherence has been associated with improved asthma control.” “Adolescents and young adult patients with mild asthma who received mometasone furoate dry powder inhaler had better adherence and post-index asthma control than those who received a non-mometasone furoate dry powder inhaled corticosteroid,” reported Dr. Navaratnam. Patients that received mometasone furoate inhaler had a higher post-index adherence of 25% compared with 17% of those patients who received an alternate inhaled corticosteroid (P < .0001). Post-index exacerbation for mometasone furoate inhaler was 0.11 versus 0.17 against another inhaled corticosteroid (P = .0055) and about 1.1 canisters of short-acting beta2-agonist canisters were used by mometasone furoate patients versus 1.5 canisters for those using alternative corticosteroid inhalers (P < .0001). Funding for this study was provided by Schering-Plough. [Presentation Title: Patient Adherence and Asthma Control in Adolescent/Young Adult Mild Asthma Patients Treated With Inhaled Corticosteroids. Abstract P85]
|
